Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02192190 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 268
- Enrollment target
NCT02192190: Clinical Trial Phase 2 study, sponsored by Eli Lilly and Company.
NCT02192190 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 268 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (102% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02192190, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 268 participants
- Enrollment target
Study Summary
The main purpose of this study is to test if LY2951742 relieves mild to moderate knee pain. The study drugs will be given as an injection under the skin and as an oral capsule. The study will last about 28 weeks for each participant.
Primary Outcome
The 24-question WOMAC Osteoarthritis Index assesses osteoarthritis (OA) symptoms using pain (5 questions), stiffness (2 questions) and physical function (17 questions) subscales. The WOMAC pain subscale was calculated for each participant at each time point for analysis as the mean score (range 0-100 millimeter \[mm\] VAS; 0=very good and 100=very poor) of all 5 questions related to pain. Bayesian posterior adjusted mean was calculated using a Bayesian Normal Dynamic Linear Model (NDLM) dose res
Interventions
- DRUG Celecoxib
- DRUG LY2951742
- OTHER Placebo- oral
- OTHER Placebo - SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 268 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Why NCT02192190 stopped before completion
NCT02192190 is an interventional study that assigns participants to a tested intervention. The registered 268 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (102% higher).
The record links to 0 conditions, and to 4 interventions - of which Celecoxib is the first listed.
NCT02192190 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02192190 about?
NCT02192190 is a clinical study titled "A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain". The main purpose of this study is to test if LY2951742 relieves mild to moderate knee pain. The study drugs will be given as an injection under the skin and as an oral capsule. The study will last about 28 weeks for each participant.
What is the current status of trial NCT02192190?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 268 participants. The study started on 2014-07. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02192190?
The interventions under investigation include: Celecoxib (DRUG), LY2951742 (DRUG), Placebo- oral (OTHER), Placebo - SC (OTHER).
Who is sponsoring clinical trial NCT02192190?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02192190's enrollment target sits among peer trials
268 208th of 2000 higher than 1,792 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
- NCT05797831 · 268 participants · Phase 2
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- NCT05997381 · 268 participants · NA
BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears
- NCT06233461 · 268 participants · Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia